Quest Pharmatech Inc V.QPT

Why did the Study fail?

[TrickyGame]

I thought the trial was going very wel? Wasn't oregovomab going to be the new Standard of Care for Ovarian Cancer? seems kind of sus to recommend stopping the trial but also recomend following up with patients?

[TrickyGame]

They still have that wound healing EFG molucule for wound healing and dermatology. That could be huge. If the wound healing application is quite effective the US military would be all over that. 

[G1945V]

I believe that the DSMB is only advising CAB to discontinue the clinical trial for interim "progression-free survival" in the study subjects due to the futility evaluation. But recommends the continuation of the study subjects in the "overall survival" study, due to the characteristics of the immunotherapy (oregovomab) drug. So it's not all lost.   (JMO) G1945V

[TrickyGame]

So you are saying the "interim progression-free survival" part of the study will be discontinued but the "overall survival" part of the study will continue? So there is still a chance that Ovarex (oregovomab's incoming brand name) will become the new Standard of Care for ovarian cancer?

[G1945V]

Yes, that's my understanding. Management should put out a simple explanation. G1945V

[ARIMA11]

Yes. They should. However, this release is very contradictory. On one hand, it not good and on the other its hopeful. Details are very sparse. Question at this point is are: 1. What is the make up of the DSMB?  Data Safety Monitoring Board (DSMB), an independent committee appointed by CAB to advise on the trials. to discontinue the clinical trial after conducting a futility evaluation

[ARIMA11]

Again, 61% of the trades today involved Anonymous brokers (1)   24-Jan 0.02 95000 1 7 24-Jan 3:29:09 PM 0.02 10,000 1 7 24-Jan 3:28:54 PM 0.02 10,000 1 7 24-Jan 12:55:23 PM 0.025 29,000 2 1 24-Jan 10:19:47 AM 0.025 29,000 1 19 24-Jan 10:19:39 AM 0.025 5,000 1 19 24-Jan 10:19:19 AM 0.025 20,000 1 9 198,000   24-Jan 3:28:54 PM 0.02 10,000 79 7 24-Jan 3:28:54 PM 0